SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is trending as investors react to a significant convertible notes offering and news that Siemens turbines have arrived for its major data center project, fueling community speculation about a looming anchor tenant deal. While some traders express frustration with the company's capital-intensive nature and governance questions, others view the recent price volatility and institutional stake-building as a prime re-entry opportunity for a long-term AI infrastructure play.

Luckin Coffee, Inc. engages in providing food and beverage items, and operates coffee retail stores. It has a pioneered a technology-driven retail network to provide coffee and other products of high quality, high convenience and high affordability to customers. The company manages pick-up stores, relax stores, and delivery kitchens. It also offers tea, snacks, and light meals through its mobile application. The company was founded by Zhi Ya Qian, Fei Yang and Jin Yi Guo on June 16, 2017 and is headquartered in Xiamen, China.

Luckin Coffee Inc - ADR

Investors are closely tracking Luckin Coffee's upcoming quarterly results, with the community actively debating whether the company can sustain its rapid expansion and store growth while managing margins. Bullish sentiment is being bolstered by recent partnerships and consistent store count increases, fueling speculation among longs about potential relisting news and a breakthrough toward higher price levels.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to the company's recent strategic debt repurchases, which signal management's confidence in near-term cash flow and future milestones, while community sentiment remains focused on upcoming European regulatory decisions and the activation of the permanent billing J-code. Shareholders are actively debating the timing of potential partnership payments and whether these financial moves indicate that the company is effectively de-risking ahead of a larger strategic event.

Ambarella, Inc. engages in the development of low-power system-on-a-chip (SoC), semiconductors, and software for edge artificial intelligence (AI) applications and intelligent automation. The firm's products include video security, advanced driver assistance (ADAS), electronic mirror, drive recorder, driver or cabin monitoring, autonomous driving, and other robotics applications. It operates through the following geographical segments: Taiwan, Asia Pacific, Europe, North America, and United States. The company was founded by Feng Ming Wang and Leslie D. Kohn on January 15, 2004 and is headquartered in Santa Clara, CA.

Ambarella Inc

Ambarella shares are surging as investors react to reports of potential acquisition interest from NXP Semiconductors, a move seen as a strategic play to bolster NXPs automotive and edge AI portfolio. While the market remains cautious due to the lack of a finalized deal and recent volatility in the semiconductor sector, the community is actively debating the potential takeover premium and the company's long-term strength as a specialist in edge AI vision chips.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is experiencing extreme volatility and a significant selloff despite reporting record revenue and raised guidance, leaving the community divided between those viewing the price drop as a buying opportunity and those concerned about the company's growth narrative. Investors are actively debating whether the stock's recent price compression is a fundamental re-rating or a temporary overreaction that sets the stage for a potential rebound.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune Group is facing significant volatility as recently released FDA briefing documents suggest a third potential rejection for its melanoma treatment, citing concerns over flawed study design and inflated efficacy data. The market reaction reflects high uncertainty leading up to the upcoming advisory committee meeting, with investors actively debating the likelihood of approval versus another complete response letter.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpool Corp. is facing significant volatility and intense investor scrutiny following a disappointing earnings report that triggered a sharp decline in share price. The community is heavily focused on the company's dividend suspension, high debt levels, and internal management challenges, with investors debating whether the stock represents a deep-value turnaround opportunity or an ongoing financial struggle.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending amid intense community speculation regarding the company's valuation, upcoming earnings expectations, and the impact of the new CEO transition. Investors are actively debating the firm's long-term potential in Duchenne muscular dystrophy treatments compared to competitors, while expressing frustration over the stock's price action and persistent short interest.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending as investors react to extreme volatility driven by conflicting signals about diplomatic talks with Iran and persistent geopolitical tensions in the Middle East. Market participants are actively debating whether price swings represent genuine supply-side disruptions or strategic market manipulation amid record-low strategic petroleum reserves.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as investors weigh strong demand for its oral Wegovy pipeline against the company's aggressive legal challenge to Eli Lilly's advertising claims. The community is actively debating the durability of the oral drug's prescription growth as a primary catalyst, with many shareholders maintaining a long-term bullish stance despite recent share price volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

NVO Stock Slumps After Late-Stage Trial Fails Primary Goal – Retail Says ‘Current Revenue Drivers’ Still Intact

Novo Nordisk shares declined following the announcement that its Phase 3 ZEUS trial of the investigational drug ziltivekimab failed to meet its primary objective of reducing major adverse cardiovascular events. Despite this, the company confirmed that the trial results will not impact its 2026 adjusted operating profit outlook and that it will continue with other ongoing studies of the medication.

Eli Lilly Stock Has Skyrocketed. Novo Nordisk Has Crashed. 1 Number Explains Why They're Not Even Close Anymore.

Key PointsBoth companies are giants in diabetes and obesity treatments...

Equity

Novo’s Phase 3 trial showed that investigational drug Ziltivekimab did not reduce major adverse cardiovascular events compared with the placebo


HIMS Stock Eyes 4-Week Losing Streak: Legal Woes Fuel ‘Very High’ Uncertainty As Analyst Sticks To ‘No Moat’ Call 

Morningstar maintained a ‘No Moat’ view, citing low telehealth barriers and offerings rivals can replicate “with relative ease.”

 VKTX Stock Lags GLP-1 Peers In July — But Viking CEO Says Its Obesity Drug Could Offer What Rivals Can’t 

Viking expects oral VK2735 Phase 3 studies to begin in Q4 and believes the pill could become the first oral dual GLP-1 agonist to reach the market.

How Will Ozempic and Wegovy Sales Aid NVO's Upcoming Q2 Results?

Novo Nordisk's Q2 results are set to spotlight Ozempic and Wegovy sales as oral launches and label expansions drive growth amid mounting competitive pressure.

Why shareholders are suing Novo Nordisk over next-generation weight-loss drug

Investors claim Novo Nordisk misled the market about CagriSema's tolerability, after disappointing clinical trial results wiped billions off its market cap...

Watch Out, Eli Lilly and Novo Nordisk: Amgen's Monthly Weight Loss Drug Has 6 Phase 3 Trials Running -- and It's Coming for Your Patients

Key PointsAmgen wants a slice of the weight loss drug market...

Novo Nordisk (NVO) Surpasses Market Returns: Some Facts Worth Knowing

Novo Nordisk (NVO) reached $50.96 at the closing of the latest trading day, reflecting a +2.6% change compared to its last close.

Where Will Novo Nordisk Stock Be in 3 Years?

Key PointsNovo Nordisk remains a step behind Eli Lilly in the weight loss drug market...

Why Is Novo Nordisk Suing Eli Lilly, and What Does it Mean for Investors?

Key PointsEli Lilly's ads don't account for a new, higher dose of Novo Nordisk's Wegovy...

Extremely Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

The stock faced an aggressive sell-off following the disappointing ZEUS late-stage trial results for ziltivekimab, causing significant market cap volatility.

Many retail investors view the recent price decline as an irrational overreaction, emphasizing that the failed drug represented a small fraction of the firm's valuation.

Investors are shifting their attention to upcoming quarterly results, with high expectations that Wegovy pill success and strong guidance will drive a swift recovery.

Traders are buzzing with theories that the company should pivot to M&A or expand existing partnerships to strengthen its pipeline and regain investor confidence.

Current Price	$47.08
Prev Close	$51.61
Open	$47.40
Dividend Yield	2.53%
50-Day Moving Average	$46.78
Beta	0.89
Avg. Volume	13.57M
PE Ratio	12.10

52-Week High	$64.16
52-Week Low	$35.12
Market Capitalization	$173.31B
EPS (Annual)	$3.49
Price to Book	7.33
Revenue Per Employee	$679,358.45

Feed

News

Sentiment

Earnings

Fundamentals

Info